Urolithin A Supplementation to Boost Immune Health

Launched by AMAZENTIS SA · Feb 9, 2023

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy Adults that do not suffer from an uncontrolled chronic medical condition that carries metabolic consequences (as assessed by the study physician)
• • BMI\<35kg/m2
• • Provide informed consent
• • Adults aged 45-70 years, both genders
• • Subjects who have not received any systemic immunosuppression in the past 6 months
• • Subjects with any medical condition that in the opinion of the investigators would compromise the study outcome or the safety of the research participant
• Exclusion Criteria:
• • Subject has any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements;
• • Clinically significant abnormal laboratory results at screening
• • Participation in a clinical research trial within 30 days prior to randomization
• • Allergy or sensitivity to study ingredients
• • Individuals who are cognitively impaired and/or who are unable to give informed consent
• • Any condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
• • Current gastrointestinal condition which could interfere with the study (e.g. IBS/IBD, diarrhea, acid reflux disease, dysphagia etc.);
• • Excessive alcohol consumption and/or a smoker
• • Concomitant use of statins
• • Engage in regular moderate or vigorous physically activities (i.e. Category 3 as per the IPAQ activity classification)
• • Concomitant use of corticosteroids, antibiotics, any anabolic steroid, creatine, whey protein supplements, casein or branched-chain amino acids (BCAAs), immune-boosting(Vitamin C, Zinc) or mitochondrial (COQ10, NAD+) supplements within 45 days prior to screening